Article info
PDFOriginal article
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
- Correspondence to Dr Robert L Avery, California Retina Consultants, 515 E. Micheltorena St., Ste. C, Santa Barbara, CA 93103, USA; Avery1{at}jhu.edu
Citation
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
Publication history
- Received October 4, 2013
- Revised November 12, 2013
- Accepted November 17, 2013
- First published December 10, 2013.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/